Position in ALKS
as of Mar 31, 2026
· filed May 12, 2026
Position Value
$3,536
-$30,040 QoQ
Shares Held
100
-91.7% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2024
9 quarters on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Common Shares in ALKS Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Mar 31, 2026DANSKE BANK A/S holds $84,030,013 across 13 Drug Manufacturers - Specialty & Generic names. ALKS ranks #8 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ZTS |
Zoetis Inc.
|
299,003 | $35,345,143 | |
| 2 | ELAN |
Elanco Animal Health Inc
|
604,233 | $14,459,295 | |
| 3 | UTHR |
UNITED THERAPEUTICS Corp
|
17,029 | $10,097,855 | |
| 4 | INDV |
Indivior Pharmaceuticals, Inc.
|
322,523 | $9,830,501 | |
| 5 | TEVA |
Teva Pharmaceutical Industries Ltd
|
284,939 | $8,582,362 | |
| 6 | NBIX |
Neurocrine Biosciences Inc
|
42,516 | $5,601,057 | |
| 7 | VTRS |
Viatris Inc
|
8,000 | $108,080 | |
| 8 | ALKS |
Alkermes plc.
This page
|
100 | $3,536 |
All Filings in ALKS
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $3,536 | 100 | Shares | Sole | 2026-05-12 | |
| 2025-12-31 | $33,576 | 1,200 | Shares | Sole | 2026-02-02 | |
| 2025-09-30 | $1,004,130 | 33,471 | Shares | Sole | 2025-11-19 | |
| 2025-06-30 | $1,325,243 | 46,321 | Shares | Sole | 2025-12-18 | |
| 2025-03-31 | $1,844,100 | 55,848 | Shares | Sole | 2025-12-18 | |
| 2024-12-31 | $4,398,007 | 152,921 | Shares | Sole | 2026-03-18 | |
| 2024-09-30 | $1,435,495 | 51,286 | Shares | Sole | 2026-03-18 | |
| 2024-06-30 | $3,776,108 | 156,685 | Shares | Sole | 2026-03-18 | |
| 2024-03-31 | $3,871,199 | 143,007 | Shares | Sole | 2026-03-18 | |
| No filing history on record for this holder in this stock. | ||||||